–
AstraZeneca and Japan’s Takeda will bid against Johnson & Johnson and OrbiMed for the Chief Scientist’s tender.
–
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at [email protected].
Thank you.
–
/By Gali Weinreb /
UK pharmaceutical company AstraZeneca plc (LSE:AZN) is the second bidder for the dedicated biotech incubator being set up by the Chief Scientist’s incubator program at the Ministry of the Economy, sources inform “Globes.”
The company will bid for the incubator tender against a consortium of OrbiMed venture capital fund and healthcare giant Johnson & Johnson (NYSE: JNJ).
“Globes” understands that in bidding for the incubator AstraZeneca will team up with Takeda Ventures Inc., the venture capital fund of Japanese drug company Takeda Pharmaceuticals Co. Ltd. (TSE: 4502).
The tender bid winner will be announced in the coming few months.
Published by www.globes-online.com
